Etidronic acid
Based on 1 publication(s) in Google Scholar
Etidronic acid (Etidronate) is an orally and intravenously active bisphosphonate. Etidronic acid inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid has anticancer activity. Etidronic acid is a chelating agent and can be used to remove heavy metal in water.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 2809-21-4
- Formula: C2H8O7P2
- Molecular Weight:206.03
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Food Additive Library
HY-L093
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Cosmetic Ingredient Compound Library
HY-L221
-
Environmental Pollutant Compound Library
HY-L247
-
Drug Fragment Library
HY-L904
Publications Citing Use of MedChemExpress (MCE) Etidronic acid
More
Biological Activity
Etidronic acid (Etidronate) (10 mM, 24 h) shows cytotoxicity, causes a decrease in the S-phase population and an increase in the G2/M population, induces p53 mutation in MCF-7 cells[3].
Etidronic acid (100 nM, 24 h) induces osteoclast apoptosis, which displays characteristics of apoptosis, including chromatin condensation and changed cellular and nuclear morphology, detected by fluorescence microscopy[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2809-21-4
-
Appearance Solid
-
Molecular Weight 206.03
-
Formula C2H8O7P2
-
Color White to off-white
-
SMILES
OC(P(O)(O)=O)(P(O)(O)=O)C
-
Synonyms
Etidronate; HEDPA; HEDP
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep
Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2. [Abstract]2022 Oct 25;41(4):111508. PMID: 36288714
Solvent & Solubility
H2O : 100 mg/mL (485.37 mM; Need ultrasonic)
DMSO : 100 mg/mL (485.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (12.13 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (12.13 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (485.37 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (620 KB)
- English - EN (620 KB)
- Français - FR (620 KB)
- Deutsch - DE (620 KB)
- Norwegian - NO (620 KB)
- Español - ES (620 KB)
- Swedish - SV (620 KB)
- Italian - IT (620 KB)
- Korean - KR (620 KB)
- Portuguese - PT (620 KB)
-
Handling Instructions (2659 KB)
References
[1]. Dunn CJ, et al. Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging. 1994 Dec;5(6):446-74. [Content Brief]
[2]. Ariyoshi T, et al. Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig. 2006;26(4):215-22. [Content Brief]
[3]. Zhou Y, et al. Cytotoxicity of etidronic acid to human breast cancer cells. Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-87-92. [Content Brief]
[4]. Zhu S, et al. In-Depth Study of Heavy Metal Removal by an Etidronic Acid-Functionalized Layered Double Hydroxide. ACS Appl Mater Interfaces. 2022 Feb 9;14(5):7450-7463. [Content Brief]
[5]. Kameda T, et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med. 1997 Aug 18;186(4):489-95. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 4.8537 mL | 24.2683 mL | 48.5366 mL | 121.3416 mL |
| 5 mM | 0.9707 mL | 4.8537 mL | 9.7073 mL | 24.2683 mL | |
| 10 mM | 0.4854 mL | 2.4268 mL | 4.8537 mL | 12.1342 mL | |
| 15 mM | 0.3236 mL | 1.6179 mL | 3.2358 mL | 8.0894 mL | |
| 20 mM | 0.2427 mL | 1.2134 mL | 2.4268 mL | 6.0671 mL | |
| 25 mM | 0.1941 mL | 0.9707 mL | 1.9415 mL | 4.8537 mL | |
| 30 mM | 0.1618 mL | 0.8089 mL | 1.6179 mL | 4.0447 mL | |
| 40 mM | 0.1213 mL | 0.6067 mL | 1.2134 mL | 3.0335 mL | |
| 50 mM | 0.0971 mL | 0.4854 mL | 0.9707 mL | 2.4268 mL | |
| 60 mM | 0.0809 mL | 0.4045 mL | 0.8089 mL | 2.0224 mL | |
| 80 mM | 0.0607 mL | 0.3034 mL | 0.6067 mL | 1.5168 mL | |
| 100 mM | 0.0485 mL | 0.2427 mL | 0.4854 mL | 1.2134 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Etidronic acid Related Classifications
HY-B0302 Related Classifications
Powered by Bioz